EUVIMEDEUVIMED entdecken
Crossref

Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study

Mona Nassief, Nancy M Lotfy

Orbit · 2024

DOI: 10.1080/01676830.2023.2232028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Orbit, 2024. Verfasst von Mona Nassief und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt. Hauptthemen laut MEDLINE: Lacrimal Apparatus Diseases, Eyelid Diseases, Lacrimal Apparatus, Lacrimal Duct Obstruction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: funding associated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To study the efficacy of cyclosporin 0.05% eye drops in the management of grade 1 and 2 acquired punctal stenosis and to compare the results with the clinical outcomes of mini-Monoka insertion. METHODS: A prospective, controlled, interventional clinical study includes all patients (16 years and older) with symptomatic epiphora and diagnosed with grade 1 or grade 2 acquired punctal stenosis. All patients undergo punctal dilatation, canalicular probing, and nasolacrimal duct irrigation. Afterwards, patients are divided into two groups: Group A: patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc.) twice daily for 6 months. Group B: patients receive mini-Monoka stent insertion in the lower canaliculus for 6 weeks. Outcome measures are changes in Munk scoring, grading of the punctum, and functional and anatomical success. Functional success is defined as Munk score 0 to 1 and FDDT grade 0-2. Anatomical success is defined as grade 3 punctum. RESULTS: Forty-two patients are included in the study, with 21 patients in each group. There were no significant differences in the Munk score between the two groups before treatment; however, group B had a significantly higher mean rank at 6 months after treatment. After treatment, the punctal size was significantly larger in group B at 4 weeks and 3 months. However, no significant difference in punctal size was detected at 6 months after treatment between the two groups. CONCLUSION: Application of cyclosporin 0.05% eye drops is a simple and efficient non-interventional method in the management of grade 1 and 2 acquired punctal stenosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacrimal Apparatus DiseasesEyelid DiseasesLacrimal ApparatusLacrimal Duct ObstructionHumansCyclosporineConstriction, PathologicProspective StudiesStents

Stichwörter der Autor:innen

CyclosporinRestasismini-Monokapunctal stenosis

Substanzen

Cyclosporine

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt.

Förderung

  • funding associated

Zitieren

APA

Nassief, M., & Lotfy, N. M. (2024). Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study. Orbit. https://doi.org/10.1080/01676830.2023.2232028

Vancouver

Nassief M, Lotfy NM. Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study. Orbit. 2024. doi:10.1080/01676830.2023.2232028

BibTeX
@article{Nassief2024,
  author = {Nassief, Mona and Lotfy, Nancy M},
  title = {Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study},
  journal = {Orbit},
  year = {2024},
  doi = {10.1080/01676830.2023.2232028}
}
Kostenlos starten →